Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice

Dogma has held that cytotoxic ablative therapy was needed to open space and allow for marrow stem cell engraftment.1 Reports by a number of investigators established that engraftment could be obtained in nonmyeloablated mice, but some dismissed this as not significant.2-6 We have modeled our initial studies on those of Brecher and coworkers5 and established that at the stem cell level, engraftment is quantitatively complete in the absence of any cytoablative treatment; the final differentiated phenotype of engraftment is determined by the ratio of host/donor stem cells.7-10 Mathematical modeling indicated that the final level of differentiated donor hematopoietic cells in transplanted mice related directly to the ratio of infused donor marrow cells to total host marrow cells.11 This relationship holds because the relative numbers of differentiated donor and host cells in transplanted mice presumably reflects the relative number of donor and host lymphohematopoietic stem cells.

These data, indicating that engraftment in a syngeneic setting was determined solely by stem cell competition, were confirmed by studies in mice subjected to 100-cGy whole-body irradiation (WBI) and transplanted with varying levels of marrow cells.12 Here with a male BALB/c to female BALB/c transplant model, engraftment generally correlated inversely with numbers of host engraftable stem cells. This level of irradiation proved to be relatively nonmyelotoxic, but quite stem cell toxic, and high levels of stable long-term multilineage chimerism could be obtained with lower, but still relatively high, levels of infused marrow cells.

These studies suggested strategies for creating nontoxic chimerism in allogeneic stem cell transplantation using (1) nonmyelotoxic, but stem cell toxic, host treatment (100 cGy) and (2) relatively high levels of donor stem cells. Initial studies with B6.SJL to BALB/c H-2 incompatible murine marrow transplants, using 100-cGy host treatment and 40 million infused marrow cells, failed to show engraftment and indicated that tolerizing approaches were probably needed.

To initiate an effective T-cell response to antigen, 2 activation signals are needed. The primary interaction is between the antigen–major histocompatibility complex (MHC) and the T-cell receptor, but an interaction between a costimulatory molecule and its receptor is also necessary. Two major costimulatory pathways continue to be defined. The B7 (CD80 and CD86) family of molecules on antigen-presenting cells (APC) binds to T-cell antigens CD28 and CTLA4,13-16 whereas CD40 molecules on APC bind to CD40 ligand on T cells.17-21 T cells receiving the MHC–antigen–T-cell receptor signal in the absence of a costimulatory signal become anergic or are depleted.22-28 However, cytotoxic T lymphocytes receiving both activation signals can then expand clonally and respond to target cells expressing the MHC-antigen complex. Blocking these costimulator pathways presented attractive approaches to establishing antigen-specific tolerance. Early studies showed survival of cardiac allografts29 and xenogeneic islet grafts in mice30 using CTLA4 Ig inhibition of the B7-CD28 pathway, although other studies indicated that blockade of either the B7-CD28 or CD40-CD40 ligand pathways alone was insufficient to permit engraftment of highly immunogenic allografts.31-33 Use of a double blockade of CD40 and CD28 pathways allowed engraftment of alloantigen MHC-mismatched cardiac and skin grafts34 and xenogeneic rat to mouse cardiac and skin grafts and pig skin to mouse grafts.35 Anti-CD40 ligand monoclonal antibody (mAb) was found to block acute and chronic graft-versus-host disease (GVHD) and to decrease alloreactive CD4⁺ thoracic duct lymphocytes.36,37 Wekerle and colleagues38 reported on costimulator blockade in mice conditioned with 300 cGy total body irradiation (TBI) and infused with hematopoietic marrow cells. They found use of CTLA4 Ig or anti-CD40 ligand mAb alone resulted in transient chimerism, but the use of both agents resulted in stable long-term hematopoietic chimerism (> 40% and > 8 months). The use of both agents was also effective in prolonging primate kidney grafts.39 

Some investigators had shown that pretreatment with allogeneic T cells may tolerize and antigen presentation without costimulation leads to T-cell nonresponsiveness.22-28 These studies focused on CD28/B7 blockade with CTLA4 Ig. CTLA4 Ig was used in combination with donor antigen, 100-cGy total-body irradiation, and immunosuppression with mycophenolate mofetil and cyclosporine to obtain hematopoietic chimerism in dogs.40 Costimulation can also be prevented by blocking anti-CD40/CD154 interaction and subsequent up-regulation of B741-43 and anti-CD40 ligand/CD40 blockade with anti-CD40 ligand mAb combined with donor cell pre-exposure was used to obtain allogeneic murine pancreatic islet grafts44-46 and xenogeneic rat islet and skin grafts in mice.47,48 

We have used spleen cell antigen pre-exposure and concomitant blockade of the CD40/CD40 ligand pathway combined with nonmyelotoxic/stem cell toxic host treatment (100 cGy) and high levels of marrow cells (40 million) in an H-2 mismatched B6.SJL to BALB/c marrow transplant model to obtain stable long-term allochimerism.

The B6.SJL(H-2^b) and CBA/J(H-2^k) mice were obtained from the Jackson Laboratory (Bar Harbor, ME). BALB/c(H-2^d) mice were obtained from Taconic Farm (Taconic, NY). Mice were certified to be specific pathogen free, housed in our animal facility, and given ad libitum access to autoclaved food and acid water. They were maintained in accordance with local and federal guidelines (Department of Health, Education and Welfare Publication, National Institutes of Health [NIH] 78-23, 1985). These studies were approved by the University of Massachusetts Institutional Animal Care and Use Committee (IACUC) Docket: IACUC approval date 3/22/99. Animal Welfare assurance number A3306-01. The mice in our facility have been tested for Sendai virus (SEN), pneumonia virus of mice (PVM), mouse hepatitis virus (MHV), minute virus of mice (MVM), mouse polio virus (GD-7), reovirus type 3 (REO-3),Mycoplasma pulmonis (MPUL), mouse parvovirus (MPV), epizootic diarrhea of infant mice virus (EDIM), lymphocytic choriomeningitis virus (LCMV), mouse adenovirus FL/K87 (MAD), ectromelia virus (ECTRO), mouse pneumonitis virus (K), and polyoma virus (POLY). They were all negative for those tests.

Normal male B6.SJL mice (age 6-8 weeks, weight 16-18 g) were used as donors and male BALB/c mice (age 6-8 weeks, weight 16-18 g) as recipients. B6.SJL marrow cells were flushed from tibia and femurs into sterile phosphate-buffered saline (PBS) with a syringe and 25-gauge needle. Sterile cells were resuspended with 5-mL pipettes into a single cell suspension and passed through a 40 μm cell strainer. Cell number was counted in crystal violet and 40 × 10⁶bone marrow cells were injected intravenously into each recipient (day 0).

Peripheral blood was collected from each transplant mouse by eye bleeding starting 3 weeks after transplantation. Fifty microliters was used to do labeling with fluorescein isothiocyanate (FITC)–conjugated CD45.1 (A-20 line, PharMingen, San Diego, CA). Donor cell percentage in recipient was determined as FITC-positive cells divided by total cell number. B6.SJL blood was used as positive control, with labeling in the range of 95% to 98%, and BALB/c blood was used as negative control with the range of 1% to 2%. FITC-conjugated CD3 (clone 17A2), biotin-conjugated CD19 (clone 1D3), and biotin-conjugated Gr-1 (clone RB6-8C5) were used to label the T cells, B cells, and granulocytes, respectively, when doing the sublineage analysis of engrafted cell phenotype. Donor cells were labeled with CD45.1 antibody. All antibodies are from PharMingen.

Normal male B6.SJL (age 6-8 weeks, weight 16-18 g) spleen cells (10 × 10⁶) were injected by tail vein 10 days before bone marrow transplant and anti-CD40 ligand antibody injected intraperitoneally immediately before the injection of B6.SJL spleen cells (day −10) and then on days −7, −3, 0, and +3 (“standard protocol”).

The MR-1 hybridoma cell line (gift from Dr Randolph Noelle, Dartmouth Medical School, Dartmouth, NH) produces murine anti-CD40 ligand mAb. The isotype of this antibody is Armenian hamster IgG, group 3, κ. Briefly, BALB/c SCID mice (Jackson Laboratory) were primed with 0.5 mL Pristane (2,6,10.14-tetramethylpentadecane; Sigma Chemical, St Louis, MO) intraperitoneally. Seven to 10 days after the Pristane priming, 2 × 10⁶ MR-1 cells (viability > 75%) were injected intraperitoneally into each of the BALB/c SCID mice. Ascites was apparent by 7 to 10 days after cell injection and was then drained with sterile needles every other day. Freshly collected ascites was incubated at 37°C for 1 hour, then 4°C overnight. After centrifugation at 3000 rpm for 30 minutes, supernatant was filtered through a 0.2-μm filter. Samples were aliquoted and stored at −80°C. These were thawed immediately before injection into mice.

Enzyme-linked immunosorbent assay (ELISA) was used to quantitate the amount of Armenian hamster IgG in the ascites. The ELISA plates (Becton Dickinson, CA) were coated with 100 μL capture antibody (affinity purified goat anti–Armenian hamster IgG) and incubated at 4°C overnight. Unknown concentration ascites and commercial anti-CD40 ligand antibody (PharMingen) were added to appropriate wells after serial dilution for 4°C overnight. Biotinylated goat antihamster IgG was added to the wells followed by avidin-horseradish peroxidase at appropriate dilutions. TMB Peroxidase EIA Substrate Kit (Bio-Rad, Hercules, CA) was used for detection and plates read at 650 nm. Standard curves were made from the commercial anti-CD40 ligand antibody preparation and unknown ascites concentrations calculated based on the standard curves.

Skin was removed from the abdomen of euthanized murine B6.SJL(H-2^b) or CBA/J(H-2^k) donors with chloride hydrate anesthesia, and the underside was gently scraped with a scalpel to remove fat and muscle. Prepared skin was placed on sterile filter paper moistened with Hanks balanced salt solution (HBSS) buffered with HEPES (pH 7.4; Sigma Chemical) and kept at room temperature until used within 2 hours. The dorsal thoracic surfaces of anesthetized recipient mice were shaved and washed with 70% ethanol. A graft bed was prepared with fine scissors by removing an area of epidermis and dermis down to the level of the intrinsic muscle. Grafts 1.0 to 1.5 cm² in area were fitted to the prepared bed without suturing and then covered with Vaseline-impregnated gauze and an adhesive plastic bandage. After 6 days, the bandage was removed. Skin graft survival was assessed 3 times a week by visual and tactile examination. Rejection was defined as the first day on which the entire epidermal surface of the graft was necrotic.

The nonparametric Wilcoxon rank-sum test is used for comparison. The trend test developed by Cuzick was used for testing trend.49 The level of statistical significance is set at .05 (2-sided). Data are presented as mean ± 1 SEM.

In the initial studies we attempted to apply the strategy of 100-cGy BALB/c host irradiation with infusion of 40 million B6.SJL marrow cells. As shown in Figure 1, at 100 cGy, there was essentially no engraftment. In a few experiments relatively low levels of engraftment have occurred sporadically, but overall at this level of irradiation with this number of cells and 100-cGy host irradiation, marrow is rejected. As shown in Figure 1, stable long-term chimerism was not achieved until sublethal levels of single-dose irradiation (400-500 cGy) were delivered to the BALB/c hosts.

In previous studies using 40 million BALB/c cells into 100- cGy–treated BALB/c hosts, we have obtained relatively high levels of chimerism, ordinarily above 60% out to 8 months after marrow infusion.12 We determined the levels of syngeneic chimerism when B6.SJL, H-2 compatible marrow cells were infused into C57BL/6 hosts. This combination should be histocompatible. As shown in Figure 2, levels between 20% and 30% chimerism were obtained. Twenty-one week engraftment was also determined in marrow, spleen, thymus, and peripheral blood. Engraftment levels of blood, spleen, thymus, and marrow were 23.2% ± 9.3%, 25.3% ± 8.2%, 28.4% ± 13.6%, and 14.9% ± 5.3%, respectively. BALB/c and C57BL/6J mice evidence different results when radiation sensitivity is assessed.50LD_50/30 values for 4-month-old female BALB/cJ and C57BL/6J mice were 616 ± 12.8 cGy and 705 ± 6.2 cGy, respectively, indicating that BALB/cJ mice were 13% more sensitive to radiation when this parameter was measured. However, if endogenous spleen colony survival was assessed, C57BL/6J had D₀ (D₀reduces survival by a factor of 0.37) values of 65 ± 4.4 cGy, whereas BALB/cJ mice gave values of 79.4 ± 5.8 cGy, indicating that C57BL/6J were 18% more sensitive to irradiation when this parameter was measured. At the most, C57BL/6J are not more than 20% more sensitive to irradiation than BALB/c mice. Thus, the present results suggest a “BALB/c equivalent” maximum for C57BL/6J engraftment, under the conditions of these experiments, of approximately 40%, significantly less than seen with a male BALB/c to female BALB/c transplantation.

We evaluated the addition of antigen pre-exposure and costimulator blockade to the model of infusing 40 million H-2 mismatched B6.SJL cells into 100-cGy–treated BALB/c hosts. Here, as described in “Materials and methods,” 10 million B6.SJL spleen cells were infused by tail vein 10 days prior to transplantation and varying dose levels of anti-CD40 ligand antibody were given immediately prior to the spleen cell infusion and thereafter on days −7, −3, 0, and +3. On day 0, 40 million B6.SJL whole marrow cells were infused into BALB/c hosts, which had received 100 cGy within 4 hours of marrow infusion. Figure3 presents long-term results in experiments evaluating graded doses of antibody in this model. Here we see that long-term allochimerism at levels ranging from 30% to 40% were obtained out to 47 weeks after marrow infusion, at the 1.6-mg per injection antibody level. If spleen cells were given with this approach, but marrow was not infused, no engraftment was seen.

Multilineage engraftment was evaluated at 22 and 35 weeks after transplantation (Figure 4). In each instance engraftment was seen in the T-cell, B-cell, and granulocyte lineages. The distribution of each type was similar to that seen in normal B6.SJL mice, although donor CD19 percentages were relatively lower in the transplanted mice. We also evaluated engraftments in marrow, spleen, blood, and thymus at 50 weeks in selected mice from this experiment (Table 1). Multiorgan engraftment was seen, but with relatively lower levels of bone marrow engraftment due to a failure of the anti-CD45.1 mAb to react with erythroid precursors.

Stable chimerism has now been observed out to 64 weeks in 2 mice given this “standard protocol” (1.6 mg anti-CD40 ligand antibody) at 29.1% and 29.3%. In a total of 30 mice, using the “standard protocol” with 1.6 mg of anti-CD40 ligand monoclonal antibody and −day 10 spleen cell pre-exposure, evaluated at 9 weeks, the mean marrow engraftment ± 1 SE was 28.9% ± 3%. Seven of the 30 mice showed no, or very low, levels of engraftment (up to 3.1%). If the 23 mice showing higher levels of engraftment were analyzed, the mean engraftment level was 37.4% ± 1.6%. These values suggest, when compared to engraftment seen with B6.SJL into C57BL/6 mice, that a relatively high level of engraftment was obtained at the cell level of 40 million donor marrow cells in these B6.SJL to BALB/c transplants, using the “standard protocol.”

We further evaluated whether a spleen cell injection was required for induction of allochimerism. We also evaluated spleen cell administration at −7 or −10 days in the same experiments. Here, as shown in Figure 5, it was clear that omission of antigen preexposure with spleen cell injection resulted in no (or very low) chimerism. Alteration between day 7 and 10 had relatively little effect, but these results indicated that, in the context of this model, spleen cell infusion was needed to obtain full allochimerism. The impact of a secondary marrow transplant of 40 million B6.SJL cells between weeks 12 and 13 was assessed in mice in these experiments (asterisks in Figure 5). There was no augmentation of engraftment seen in groups I and V to VIII, but the 0 cGy groups treated with CD40 ligand antibody, and especially with spleen presensitization, showed an augmentation of engraftment, suggesting that secondary transplantation may be useful in these models.

We next investigated whether altering cell dose would affect allochimerism. In Figure 6 we show results when 40 million, 80 million, or 120 million marrow cells were infused in the “standard protocol.” Increasing the number of cells to 80 million significantly increased allochimerism, whereas there was little further increase with an increase to 120 million cells. Evaluation of engraftment in the spleen, thymus, marrow, and blood of 2 mice in the 80 million and 2 mice in the 120 million cell groups showed multiorgan engraftment that was relatively similar for all groups except thymus, which showed higher levels (data not shown) of engraftment, as compared to the other tissues.

The previous data showing an antibody dose-response curve out to 41 weeks was followed by further escalations of antibody levels in the “standard protocol.” In Figure 7 we show that increasing anti-CD40 ligand antibody to 3.2 mg/injection further increased the level of allochimerism. In separate studies (data not shown) we have established that 1.6 mg of control hamster IgG used, instead of anti-CD40 ligand antibody, in the full spleen pre-exposure costimulator blockade B6.SJL to BALB/c transplant model did not result in allochimerism. In further studies we have used ELISA to determine anti-CD40 ligand hamster mAb levels in murine blood. Levels of antibody remained detectable out to 15 weeks after the initial antibody course, but were undetectable at 38 weeks (Figure8). Two mice were also tested at 68 weeks and anti-CD40 ligand antibody was not detected.

Finally, we have tested the presence of antigen-specific tolerization evaluating acceptance of donor B6.SJL(H-2^b) and third-party CBA/J(H-2^k) skin grafts into H-2 mismatched BALB/c mice, which had been subjected to B6.SJL spleen cell infusions with or without anti-CD40 ligand antibody blockade. Here B6.SJL marrow was infused into 100-cGy–treated hosts (the “standard protocol”) and 8 to 9 and 39 to 43 weeks later BALB/c mice evaluated for acceptance or rejection of donor or third-party skin grafts. As shown in Table2 skin donor grafts in marrow allochimeric mice were accepted and third-party CBA/J grafts rapidly rejected. Skin graft acceptance was durable out to 31 weeks. Control transplanted mice without marrow allochimerism or nontransplanted control BALB/c mice rejected both B6.SJL and CBA/J skin grants. Mice that received the double transplant (Figure 5) were grafted with both B6.SJL and CBA/J skin grafts at 37.5 weeks after first marrow infusion. One mouse was evaluated in group VII and 2 mice in group VIII. All skin grafts were promptly rejected.

The present results establish a unique model for creation of nontoxic long-term stable high-level hematopoietic allochimerism. We have shown that antigen preexposure with concomitant CD40/CD40 ligand costimulator blockade allows for high levels of chimerism with transplantation of 40 million H-2 mismatched B6.SJL marrow to 100-cGy–treated BALB/c hosts. All components of the protocol appear essential because omission of antibody, spleen cell infusions, or irradiation results in low or absent levels of chimerism. The chimerism is long-term, over half the mouse's life span, and without evidence of GVHD. It is multilineage and shows a dose-response curve with regard to antibody dose. This dose-response result is of interest, especially given the relatively high amounts of CD40 ligand antibody demonstrating a clear dose response. This probably relates to the completeness of the costimulator blockade. This may be particularly so with a regimen including antigen (spleen cell) pre-exposure. Based on transplantation of 40 million B6.SJL marrow cells to 100-cGy–treated C57BL/6 hosts (a histocompatible combination) the chimerism averaging 20% to 30% in B6.SJL to BALB/c hosts may be close to maximal for this level of infused cells, although higher levels of chimerism are seen when 40 million male BALB/c cells are transplanted to 100-cGy–treated female BALB/c hosts. However, increasing the level of transplanted B6.SJL cells to 80 million virtually doubled allochimerism and increasing the antibody level to 3.2 mg/injection also increased the level of allochimerism. Thus chimerism can be obtained with a low-dose radiation regimen and with minimal toxicity. Although hamster immunoglobulin has been reported to accelerate collagen-induced arthritis,51it showed no activity in inducing tolerance in our model.

In work by Markees and colleagues47,48 similar antigen-specific costimulator blockade approaches with skin allografts were evaluated with challenge skin grafts from the donor strain. Five mice whose primary skin allograft had survived for over 125 days showed variable results with the challenge grafts: one mouse rejected the challenge graft but retained the primary graft, one mouse accepted the challenge graft and maintained the primary graft, whereas 3 mice rejected both the primary and challenge grafts.47,48 Our initial studies with donor and third-party skin grafts in mice maintaining their marrow allografts show tolerance to donor skin grafts with rejection of the third-party skin grafts. Thus these mice show antigen-specific tolerance to both the marrow and late-skin H-2 mismatched allografts. Conversely, mice given a second marrow transplant (Figure 5) and then a skin graft showed prompt rejection of both donor and third-party skin grafts, while maintaining their marrow grafts, presumably a form of split tolerance.

Standard marrow transplantation approaches have used high-dose ablative chemo/radio therapy for tumor killing to facilitate engraftment and to remove immune barriers. These approaches have an early treatment-related mortality and morbidity and still run the risk of graft rejection or GVHD. Solid organ transplantation has also required immediate and long-term immunosuppressive therapy with attendant risks. A number of attempts have been made to obtain allochimerism with less toxic/immunosuppressive therapy. Ildstad and colleagues52-55 have used a variety of approaches to lower WBI, including elimination of CD4⁺ and CD8⁺host T cells, cytoxan and antilymphocyte globulin treatment along with manipulation of T-cell receptor–CD8⁺ facilitator cells.56 Sykes and colleagues57 have achieved allochimerism without myelosuppressive host conditioning, using a B10.A to B6 marrow transplant model with depleting anti-CD4 and anti-CD8 mAbs, local thymic irradiation, and a high dose (174 × 10⁶) of major histocompatibility–mismatched (B10.A) marrow cells divided over days 0 through 4. These investigators, as noted above, recently used combined costimulator blockade with a WBI dose of 300 cGy, a lower dose of marrow, and no T-cell–depleting antibodies or thymic irradiation, and obtained long-term stable hematopoietic chimerism. More recently, using a congenic H-2 mismatched model (a less rigorous transplant model than B6.SJL to BALB/c), 200 million marrow cells into nonirradiated hosts with CD40 ligand mAb and CTLA4 Ig treatment, Wekerle and colleagues58 obtained low-level multilineage chimerism in 9 of 14 transplanted mice out to 30 weeks. This was similar to the levels of engraftment at 31 weeks demonstrated in our delayed transplants with no irradiation and with or without spleen cell pre-exposure presented in Figure 4 (groups II and IV). These BALB/c mice received a total of 80 million B6.SJL cells. Storb and colleagues, using posttransplantation immune suppression/modulation with cyclosporine and mycophenolate mofetil in a DLA identical canine transplant model, have also significantly lowered the irradiation dose needed to obtain allochimerism.59 Reisner and colleagues60-63 have suggested that stem cells expressing class I and class II without costimulator expression may be tolerizing and that high levels of purified stem cells may provide a means of obtaining long-term tolerance. In a related vein, others have suggested that various marrow cell populations could induce specific tolerance to donor-type antigens either by exhibiting specific suppression or inducing anergy of cytotoxic T-lymphocyte progenitors. These subpopulations include “natural” suppressors64; CD8 nonalloreactive T cells65; CD8⁺, CD3⁺, CD45 R⁺, Thy-1⁺, and TCR⁻ “facilitator” cells56; and CD2⁺, CD8⁺, CD16⁺, DR⁻, CD3⁻, and CD38⁻cells.66 

Thus, part of the effectiveness of our approach, using antigen-specific preexposure combined with anti-CD40 ligand blockade, high levels of marrow cells, and nonablative (100 cGy) host treatment, may be the infusion of appropriate numbers of tolerizing stem cells or tolerizing cells without stem cell potential. In addition, Ferrara67has described the phenomenon of “cytokine storm” occurring with cytoablative therapy and potentially inducing GVHD. Low-dose host treatment would minimize or eliminate this potentially deleterious effect. Finally, costimulator blockade in the context of antigen presentation is a specific approach for inducing antigen-specific tolerance. Thus, the present approach combines multiple elements that may induce tolerance or diminish immune reactivity as presented in Table 3.

The model described here is both nontoxic and flexible. It would appear that the percent donor chimerism can be altered by altering the cell level infused or antibody level injected. In unpublished studies (H.W., S.Z., F.M.S., P.J.Q.) we have shown that 30% to 40% chimerism in Hbb^th/Hbb^th thalassemia mice68corrects the anemia of these mice. Other studies have shown that partial allochimerism in human thalassemia transplant potentially leads to correction of the anemia.69,70 These data suggest that the present approach might be used in humans to purposefully create nontoxic partial allochimerism to correct the anemia in patients with thalassemia or sickle cell anemia.69-71 This type of approach using CD40 ligand mAb for a costimulator blockage might be complicated by thromboembolic toxicity as recently observed in both primates and humans.72,73 However, this has not been a universal experience, and the specifics of the antibody preparation rather than the CD40-CD40 ligand blockade may be the problem.72 Similar approaches will be of interest in the immune therapy of cancer and in transplant for autoimmune diseases.